… antigen content dTpa vaccine successfully induced a booster response to vaccine antigens
… following booster vaccination with a reduced antigen content vaccine in children previously …

… Modern acellular reduced-antigen-content vaccines have been developed, … the
immunogenicity and reactogenicity of Boostrix™, GlaxoSmithKline Biologicals’ reduced-antigen-content …

… the aluminium content has a specific influence on the immunogenicity of this dTpa vaccine.
… contribution of aluminium to the immunogenicity and safety of a combined, reduced antigen …

… The antigen content of the vaccine was adjusted to yield 20 mouse protective dosesso in
the mouse challenge potency test described below. The first two doses were given with an …

… also with a higher dose (40 μg) of antigen in the experimental vaccine compared to the
licensed vaccine (20 μg). This higher antigen content could, at least in part, also be responsible …

… being the increase in reactogenicity with each successive dose. The aim of this study was
to assess the immunogenicity, safety and reactogenicity of a reduced antigen, combined dTpa …

… markers of vaccine immunogenicity and reactogenicity: (1) … reactogenicity and immunogenicity
will significantly improve. … a robust antibody response to influenza antigens. Citation41 …

… reactogenic profile of licensed DTPa vaccines it is logical to assess the ability of the `low-dose'
booster with reduced antigen contents … compare the reactogenicity and immunogenicity of …

… The association between reactogenicity and antibody levels in men was striking. Yet sex
is known to play an important role in immune response to self and foreign antigens. Females …

… , we assessed immunogenicity and reactogenicity 28 … antibodies, and the secondary end
points were the levels of neutralizing antibodies, S-specific T-cell responses, and reactogenicity…